Advertisement
U.S. markets close in 6 hours 8 minutes
  • S&P 500

    5,253.21
    +4.72 (+0.09%)
     
  • Dow 30

    39,766.76
    +6.68 (+0.02%)
     
  • Nasdaq

    16,416.97
    +17.45 (+0.11%)
     
  • Russell 2000

    2,121.66
    +7.32 (+0.35%)
     
  • Crude Oil

    82.54
    +1.19 (+1.46%)
     
  • Gold

    2,227.30
    +14.60 (+0.66%)
     
  • Silver

    24.72
    -0.03 (-0.13%)
     
  • EUR/USD

    1.0817
    -0.0013 (-0.12%)
     
  • 10-Yr Bond

    4.2220
    +0.0260 (+0.62%)
     
  • GBP/USD

    1.2643
    +0.0005 (+0.04%)
     
  • USD/JPY

    151.2350
    -0.0110 (-0.01%)
     
  • Bitcoin USD

    70,877.29
    +334.86 (+0.47%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,969.15
    +37.17 (+0.47%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

GlaxoSmithKline's 'Unexpected Disappointment'

  • GlaxoSmithKline plc (ADR) (NYSE: GSK) is near its 52-week lows after having fallen 6.2 percent this year.

  • Following topline results from GlaxoSmithKline's SUMMIT study, Goldman Sach's Keyur Parekh called the results an "unexpected disappointment."

  • For GSK financially, the results were only a "marginal disappointment," Parekh said, though the result "raises deeper questions" around GSK's management.

GlaxoSmithKline released results from its SUMMIT study earlier this week, which failed to meet the goal when studying BREO in patients with COPD. Those results did show that BREO was associated with a lower risk of dying; however, the results were not statistically significant. That was an "unexpected disappointment," according to Goldman's Parekh.

But the fiscal impact from this would be "marginal," Parekh noted. In 2020, Goldman models £1 billion in revenue – a number that is "unlikely" to be challenged by these results. However, for Parekh, the bigger issue is how these results cast doubt on GSK's "overall R&D strategy and spend."

Goldman's solution – GSK should narrow its therapeutic focus and reassess its overall R&D spend. That could lead the company to "meaningfully improve" its R&D productivity. If these results serve as the catalyst to push GSK management to focus more, "it could act as a LT silver lining," Parekh said.

Goldman reiterated its estimates, ratings and price target.

Much of GlaxoSmithKline's year-to-date losses have come in the past month, when the stock shed 10.5 percent. At present levels, the stock yields 6.2 percent.

Latest Ratings for GSK

Jun 2015

Morgan Stanley

Downgrades

Overweight

Equalweight

Jan 2015

New Street Research

Downgrades

Jul 2014

Mainfirst

Downgrades

Underperform

View More Analyst Ratings for GSK
View the Latest Analyst Ratings

See more from Benzinga

© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement